Home > Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD[1]), a biopharmaceutical company focused on
innovative oncology therapies, today announced the full efficacy
and safety data from its Phase 3 SPEAR (Study of Picoplatin
Efficacy After Relapse) trial of picoplatin in the second-line
treatment of small cell lung cancer (SCLC). Dr. Tudor Eliade
Ciuleanu, M.D., Ph.D., of Institute of Oncology, Cluj-Napoca, Romania and an investigator for the
SPEAR trial, presented the data during an oral session at the
American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in
Chicago, IL.

"Results from this important study show that picoplatin is an
active compound, with a demonstrated survival benefit among
patients where the use of post-study chemotherapy between treatment
arms was balanced," stated Dr. Ciuleanu. "These data include
a number of significant outcomes, including improved overall
survival among those individuals who did not receive post-study
chemotherapy, the study's principal confounding factor, and among
early relapsing or platinum refractory patients, a clinically
meaningful population. Further, picoplatin exhibits a
manageable safety profile consistent with prior clinical
experience. These results warrant further investigation in this
indication."

SOUTH SAN FRANCISCO , June 5 /- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in...